Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort

被引：61

作者：

Petri, M. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD 21205 USA

来源：

LUPUS | 2010年 / 19卷 / 04期

关键词：

anti-cardiolipin antibodies; anti-phospholipid syndrome; lupus anticoagulant; VENOUS THROMBOSIS; ENDOTHELIAL-CELLS; ERYTHEMATOSUS; ANTICOAGULANT; RISK;

D O I：

10.1177/0961203309360541

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Anti-phospholipid antibodies are common in patients in the Hopkins' Lupus Cohort: 47% have anti-cardiolipin, 32.5% anti-beta(2)- glycoprotein I and 26% lupus anticoagulant (by dRVVT confirmatory testing). Systemic lupus erythematosus patients with the lupus anticoagulant at baseline have a 50% chance of a deep venous thrombosis/pulmonary embolus in the next 20 years. Anti-phospholipid antibodies differ in their association with thrombosis: the lupus anticoagulant is most strongly associated with arterial and venous thrombosis and is the only anti-phospholipid antibody associated with myocardial infarction. Anti-phospholipid antibodies are not associated with atherosclerosis. Lupus (2010) 19, 419-423.

引用

页码：419 / 423

页数：5